Patent: 12,383,611
✉ Email this page to a colleague
Summary for Patent: 12,383,611
| Title: | Neisseria meningitidis compositions and methods thereof |
| Abstract: | In one aspect, the disclosure relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide, and methods of use thereof. The disclosure further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants. |
| Inventor(s): | Annaliesa Sybil Anderson, John Lance Perez, Kathrin Ute Jansen, Paul Liberator, Cuiwen Tan, Thomas Richard Jones, Johannes Frederik Beeslaar, Judith Absalon, Jason Douglas Maguire, Shannon Lea Harris |
| Assignee: | Pfizer Corp SRL |
| Application Number: | US17/764,153 |
| Patent Claims: | see list of patent claims |
Details for Patent 12,383,611
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Pfizer Ireland Pharmaceuticals Unlimited Company | PENBRAYA | meningococcal groups a, b, c, w, and y vaccine | Injection | 125770 | October 20, 2023 | 12,383,611 | 2040-09-24 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 12,383,611
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2020355401 | ⤷ Start Trial |
| Brazil | 112022004921 | ⤷ Start Trial |
| Canada | 3155669 | ⤷ Start Trial |
| China | 115605222 | ⤷ Start Trial |
| European Patent Office | 4034157 | ⤷ Start Trial |
| Israel | 291239 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
